Explore BioBoost LabsBody & Peptide Science · System 05
Metabolic & Energy
How gut and pancreatic hormone receptors, plus the cell’s own energy machinery, are studied in the research literature. Education only, not medical advice.
01
The system at a glance
Every meal sets off a cascade of chemical messengers. Hormones released from the gut and pancreas tell the brain you are full, tell the stomach to slow down, and tell the pancreas to fine-tune insulin and glucagon so blood sugar stays in a narrow band. Deeper inside, mitochondria and the redox cofactor NAD+ run the machinery that actually turns fuel into usable energy. The compounds on this page are research tools grouped by where they act on that map: the incretin and amylin receptor signals that coordinate appetite and glucose, and the mitochondrial and enzyme pathways that govern how cells store versus burn fuel. This page describes what the peer-reviewed literature documents about their mechanisms and the models they were studied in. It is strictly educational and describes no protocol, dose, or use.
02
How it signals
Two conversations run in parallel. The first is hormonal: incretins (GLP-1, GIP, glucagon) and amylin are messengers that surge after eating and act on receptors in the pancreas, gut, and brain to shape insulin release, gastric emptying, and the sensation of fullness. Receptor engineers have learned to build single, dual, and triple-receptor research peptides that pull several of these levers at once. The second conversation is intracellular: enzymes like NNMT, mitochondrial-derived peptides like MOTS-c, and the NAD+ cofactor pool set how efficiently a cell burns fuel versus stores it as fat. Studying either conversation is how researchers map metabolism at the level of mechanism.
03
Research peptides studied in this system
Each card summarizes the documented mechanism, what was actually studied and in what model, and how strong the evidence is. These are descriptions of laboratory research — not recommendations, and not evidence of benefit in humans. According to research indexed in PubMed:
Bio R/3Triple-receptor research peptide (GLP-1 / GIP / glucagon)Moderate — defined receptor pharmacology; clinical data for the triple-agonist class still maturing
Documented mechanism
A single engineered peptide designed to activate three incretin-family receptors at once: GLP-1 (glucose-dependent insulin release, appetite suppression, slowed gastric emptying), GIP (insulin secretion and adipose signaling), and glucagon (which in this context is studied for its effect on energy expenditure and hepatic fat handling). The research rationale is that simultaneously engaging all three may address body weight, insulin resistance, and liver fat through complementary routes rather than one pathway alone. 12
What was actually studied
Reviewed in the context of metabolic dysfunction-associated steatohepatitis and obesity biology, drawing on human clinical-trial programs for gut-hormone agonists; the optimal balance of glucagon and GIP activity relative to GLP-1 is described as still an open research question. Note: no triple GLP-1/GIP/glucagon agonist is yet approved as a medicine; approved incretin medicines target the related single (GLP-1) and dual (GIP/GLP-1) receptor combinations.
Evidence tier
The relative contribution of each receptor arm is genuinely unsettled in the literature, and whether benefits are direct or downstream of weight and insulin changes is debated. Combining receptor activities can also compound the side-effect burden.
Bio S/1Single-receptor research peptide (GLP-1)Higher — GLP-1 receptor biology is among the most thoroughly characterized in metabolic research
Documented mechanism
Selectively activates the GLP-1 receptor, a class B G-protein-coupled receptor. Endogenous GLP-1 is released from gut enteroendocrine cells after eating and augments glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces food intake via receptor-expressing neurons — a combination that improves glycemic excursions while limiting weight gain. 23
What was actually studied
Mechanisms mapped across rodent, non-human primate, and human studies, including high-resolution structural work showing exactly how agonists dock in the receptor and bias its downstream signaling. This receptor class includes approved medicines.
Evidence tier
The signaling is well understood, but ‘biased’ agonism (favoring G-protein over beta-arrestin pathways) and species differences in the receptor mean findings do not always translate cleanly between models.
Bio T/2Dual-receptor research peptide (GIP / GLP-1)Higher — dual GIP/GLP-1 co-agonism supported by large human trial programs
Documented mechanism
A co-agonist engineered to activate both the GIP and GLP-1 receptors, which are co-expressed in the pancreas and in brain regions regulating food intake. The research hypothesis is that adding GIP-receptor activity to GLP-1 activity produces additive effects on insulin sensitivity, insulin secretion, and appetite beyond GLP-1 alone. 41
What was actually studied
The GIP and GLP-1 incretin receptors are among the best-characterized in human metabolic research, and the dual GIP/GLP-1 receptor combination is targeted by an approved incretin medicine.
Evidence tier
A real mechanistic puzzle remains: GIP reduces intake and weight in rodents, but that effect has not been clearly demonstrated in humans, and whether GIP-receptor agonism or antagonism is optimal is still argued in the literature.
Amylin AnalogAmylin (islet amyloid polypeptide) receptor agonistModerate — core amylin mechanism established; newer long-acting research analogs less mature
Documented mechanism
Mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. It acts on amylin receptors to slow gastric emptying, suppress inappropriate post-meal glucagon secretion, and increase satiety — complementing insulin by controlling how quickly glucose appears in the blood after a meal rather than acting on glucose disposal directly. 5
What was actually studied
The reference amylin analog (pramlintide) has long-term human clinical-trial data as an adjunct to mealtime insulin, showing effects on post-meal glucose and body weight; this anchors the mechanism for the broader amylin-analog research class.
Evidence tier
The three-part mechanism (gastric emptying, glucagon, satiety) is well documented for the established analog, but many newer research analogs are early-stage and their profiles should not be assumed identical.
AOD-9604Synthetic C-terminal fragment of human growth hormone (lipolytic fragment)Lower — mechanism from rodent models; human metabolic data limited and inconsistent
Documented mechanism
A short peptide fragment derived from the C-terminus of growth hormone, studied for lipolytic (fat-mobilizing) activity that appears separable from growth hormone’s effects on blood sugar and growth. In animal work it increased fat oxidation and energy expenditure and raised expression of the beta-3 adrenergic receptor, the main lipolytic receptor on fat cells. 6
What was actually studied
Chronic-dosing studies in obese mice and beta-3-receptor knockout mice indicated its fat-reducing action increases beta-3 receptor expression but is not exerted directly through that receptor; an acute effect on energy expenditure persisted even without the receptor.
Evidence tier
Evidence is predominantly rodent and mechanistic. Human data for meaningful metabolic effects are limited and have not consistently reproduced the animal findings.
5-Amino-1MQSmall-molecule NNMT (nicotinamide N-methyltransferase) inhibitorLower — preclinical cell and rodent evidence only
Documented mechanism
A membrane-permeable small molecule that inhibits NNMT, an enzyme abundant in fat tissue. NNMT consumes methyl groups and nicotinamide; blocking it is studied as a way to raise intracellular NAD+ and SAM (S-adenosylmethionine) levels and to suppress lipogenesis, shifting adipocytes away from fat storage. 7
What was actually studied
In cultured adipocytes, selective NNMT inhibitors reduced the reaction product 1-methylnicotinamide, raised NAD+ and SAM, and suppressed fat synthesis; in diet-induced obese mice a potent inhibitor lowered body weight, white-fat mass, adipocyte size, and cholesterol without changing food intake.
Evidence tier
All supporting data are preclinical (cell and mouse). NNMT is a validated target in that setting, but human efficacy and safety are not established.
MOTS-cMitochondrial-derived peptide (12S rRNA-encoded)Lower — preclinical mechanistic and review-level evidence; no established human use
Documented mechanism
A 16-amino-acid peptide encoded within the mitochondrial genome. Under metabolic stress it moves to the nucleus and helps regulate nuclear gene expression, acting as a signal that links mitochondrial state to whole-cell metabolism. It has been associated with improved glucose handling in skeletal muscle, and circulating levels decline with age. 8
What was actually studied
Described mechanistically and in reviews across tissue and rodent models in the context of insulin resistance, aging, and metabolic stress responses; a clinically established application does not yet exist.
Evidence tier
The biology is compelling but early. Much of the evidence is mechanistic or review-level, and no validated clinical use has been developed.
NAD+Nicotinamide adenine dinucleotide (and precursors such as NMN)Moderate — strong rodent mechanism; human translation still under active study
Documented mechanism
NAD+ is a central redox cofactor that mitochondria use to convert fuel into ATP and that sirtuin enzymes use to regulate metabolism. Cellular NAD+ availability declines with age and in some disease states; precursors like nicotinamide mononucleotide (NMN) are studied as a way to replenish the NAD+ pool and support mitochondrial and energy metabolism. 9
What was actually studied
Long-term oral NMN in normally aging mice was rapidly converted to NAD+ in tissues and was associated with enhanced energy metabolism, better insulin sensitivity and lipid profile, and improved mitochondrial oxidative metabolism in skeletal muscle, without obvious toxicity in that model.
Evidence tier
The strongest data are from mice. Human trials of NAD+ precursors are ongoing, and whether measured biochemical increases produce meaningful physiological benefit in people remains an open question.
Lipo-CLipotropic combination (choline, methionine, inositol and related methyl donors)Lower — nutrient biology established; combination-product evidence weak
Documented mechanism
Lipotropes are nutrients — chiefly choline, methionine, inositol, betaine, and folate — involved in exporting fat from the liver (via VLDL packaging), in methyl-group metabolism, and in DNA methylation. The research concept behind lipotropic combinations is that supplying these methyl donors supports hepatic lipid handling; deficiency of choline and methionine is a well-established way to induce hepatic fat accumulation in models. 10
What was actually studied
The individual lipotrope biology is documented in nutrition reviews linking methionine, choline, and inositol to hepatic protection and lipid metabolism.
Evidence tier
Evidence supports the underlying nutrient biology, not the branded injectable combinations. Rigorous data that a lipotropic ‘cocktail’ changes body composition in otherwise-replete people are lacking.
04
What we don’t know — and the risks
Honest limits matter as much as the mechanisms. For this system specifically:
- This page is educational and describes mechanisms and research models only. It is not medical advice and contains no dosing, timing, protocol, or how-to guidance.
- All compounds here are for research use only (RUO). Several — including AOD-9604, 5-Amino-1MQ, MOTS-c, and lipotropic combinations — have evidence limited largely to cell or animal models, and animal findings often fail to translate to humans.
- For the incretin and amylin receptor classes, note that engaging these pathways affects gastric emptying, appetite, and glucose regulation; the literature also documents gastrointestinal effects and unresolved mechanistic questions (for example, GIP’s role in humans).
- Evidence tiers on this page (l = lower / m = moderate / h = higher) reflect the maturity and consistency of the published mechanism, not a safety rating and not an endorsement of any use.
- Nothing here should be read as a claim that any compound diagnoses, treats, cures, or prevents disease.
05
Responsible understanding
◆ This is education, not medical advice
This page is educational and describes what has been studied in laboratory and clinical research. It is not medical advice, and these materials are for research use only — not for human or veterinary use. Timing, administration, and whether anything is used at all are clinical decisions that belong with a licensed physician overseeing your care; we take no position on them. Science and regulation evolve; verify anything important against the primary sources below.
06
Sources
Based on articles retrieved from PubMed. Follow each link to the original paper.
- Newsome PN, Ambery P Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver Journal of Hepatology. 2023;J Hepatol. 2023;79(6):1557-1565. DOI
- Drucker DJ Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell Metabolism. 2018;Cell Metab. 2018;27(4):740-756. DOI
- Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist Proceedings of the National Academy of Sciences USA. 2020;Proc Natl Acad Sci USA. 2020;117(47):29959-29967. DOI
- Baggio LL, Drucker DJ Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57. DOI
- Pullman J, Darsow T, Frias JP Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes Vascular Health and Risk Management. 2006;Vasc Health Risk Manag. 2006;2(3):203-212. DOI
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice Endocrinology. 2001;Endocrinology. 2001;142(12):5182-5189. DOI
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice Biochemical Pharmacology. 2017;Biochem Pharmacol. 2017;147:141-152. DOI
- Zheng Y, Wei Z, Wang T MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation Frontiers in Endocrinology. 2023;Front Endocrinol (Lausanne). 2023;14:1120533. DOI
- Mills KF, Yoshida S, Stein LR, et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice Cell Metabolism. 2016;Cell Metab. 2016;24(6):795-806. DOI
- Fardet A New hypotheses for the health-protective mechanisms of whole-grain cereals: what is beyond fibre? Nutrition Research Reviews. 2010;Nutr Res Rev. 2010;23(1):65-134. DOI
Body & Peptide Science · Metabolic & Energy · Draft for review
Research-use-only educational content. Nothing here is medical, dosing, timing, or treatment advice.
Research-use-only educational content. Nothing here is medical, dosing, timing, or treatment advice.